ATE250416T1 - Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin - Google Patents
Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidinInfo
- Publication number
- ATE250416T1 ATE250416T1 AT97933264T AT97933264T ATE250416T1 AT E250416 T1 ATE250416 T1 AT E250416T1 AT 97933264 T AT97933264 T AT 97933264T AT 97933264 T AT97933264 T AT 97933264T AT E250416 T1 ATE250416 T1 AT E250416T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- thiazolidine
- administration
- treating
- neurodegenerative diseases
- Prior art date
Links
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2157196P | 1996-07-11 | 1996-07-11 | |
| PCT/US1997/011586 WO1998002160A1 (en) | 1996-07-11 | 1997-07-01 | Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE250416T1 true ATE250416T1 (de) | 2003-10-15 |
Family
ID=21804973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97933264T ATE250416T1 (de) | 1996-07-11 | 1997-07-01 | Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5912259A (de) |
| EP (1) | EP0914122B1 (de) |
| JP (1) | JP2001508028A (de) |
| KR (1) | KR20000023683A (de) |
| CN (1) | CN1145481C (de) |
| AT (1) | ATE250416T1 (de) |
| AU (1) | AU726664B2 (de) |
| BR (1) | BR9710467A (de) |
| CA (1) | CA2255073A1 (de) |
| CO (1) | CO4940509A1 (de) |
| DE (1) | DE69725147T2 (de) |
| DK (1) | DK0914122T3 (de) |
| ES (1) | ES2205247T3 (de) |
| HR (1) | HRP970362A2 (de) |
| IL (1) | IL127487A (de) |
| NO (1) | NO990076D0 (de) |
| NZ (1) | NZ332763A (de) |
| PL (1) | PL331049A1 (de) |
| PT (1) | PT914122E (de) |
| TR (1) | TR199900040T2 (de) |
| WO (1) | WO1998002160A1 (de) |
| ZA (1) | ZA976142B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003104423A2 (en) * | 2002-06-11 | 2003-12-18 | Roy Ogle | Meningeal-derived stem cells |
| WO2009137109A1 (en) * | 2008-05-08 | 2009-11-12 | Rutgers, The State University | Endorphin therapy compositions and methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT83152B (pt) * | 1985-08-09 | 1989-03-30 | Lilly Co Eli | Processo para a preparacao de compostos di-t-butilfenoicos |
| DE69027472T2 (de) * | 1989-04-07 | 1996-12-05 | Lilly Co Eli | Arylsubstituierte Rhodaninderivate |
| US5143928A (en) * | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
| US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
| CZ181493A3 (en) * | 1992-09-10 | 1994-03-16 | Lilly Co Eli | The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease |
| EP0722729A3 (de) * | 1995-01-23 | 1997-11-26 | Eli Lilly And Company | Aryl-substituierte Rhodaninen zur Behandlung multipler Sklerose |
| ATE301457T1 (de) * | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
-
1997
- 1997-07-01 IL IL12748797A patent/IL127487A/en not_active IP Right Cessation
- 1997-07-01 ES ES97933264T patent/ES2205247T3/es not_active Expired - Lifetime
- 1997-07-01 DE DE69725147T patent/DE69725147T2/de not_active Expired - Fee Related
- 1997-07-01 EP EP97933264A patent/EP0914122B1/de not_active Expired - Lifetime
- 1997-07-01 PT PT97933264T patent/PT914122E/pt unknown
- 1997-07-01 CA CA002255073A patent/CA2255073A1/en not_active Abandoned
- 1997-07-01 WO PCT/US1997/011586 patent/WO1998002160A1/en not_active Ceased
- 1997-07-01 JP JP50606698A patent/JP2001508028A/ja not_active Ceased
- 1997-07-01 DK DK97933264T patent/DK0914122T3/da active
- 1997-07-01 AU AU36491/97A patent/AU726664B2/en not_active Ceased
- 1997-07-01 PL PL97331049A patent/PL331049A1/xx unknown
- 1997-07-01 CN CNB971960429A patent/CN1145481C/zh not_active Expired - Fee Related
- 1997-07-01 US US09/171,891 patent/US5912259A/en not_active Expired - Fee Related
- 1997-07-01 TR TR1999/00040T patent/TR199900040T2/xx unknown
- 1997-07-01 NZ NZ332763A patent/NZ332763A/xx unknown
- 1997-07-01 BR BR9710467A patent/BR9710467A/pt not_active Application Discontinuation
- 1997-07-01 AT AT97933264T patent/ATE250416T1/de not_active IP Right Cessation
- 1997-07-03 HR HR60/021,571A patent/HRP970362A2/xx not_active Application Discontinuation
- 1997-07-10 ZA ZA9706142A patent/ZA976142B/xx unknown
- 1997-07-10 CO CO97038493A patent/CO4940509A1/es unknown
-
1999
- 1999-01-08 NO NO990076A patent/NO990076D0/no not_active Application Discontinuation
- 1999-01-09 KR KR1019997000140A patent/KR20000023683A/ko not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69725147D1 (de) | 2003-10-30 |
| ZA976142B (en) | 1998-02-02 |
| KR20000023683A (ko) | 2000-04-25 |
| AU3649197A (en) | 1998-02-09 |
| HK1020533A1 (en) | 2000-05-12 |
| IL127487A0 (en) | 1999-10-28 |
| NZ332763A (en) | 2000-07-28 |
| PT914122E (pt) | 2003-12-31 |
| NO990076L (no) | 1999-01-08 |
| DK0914122T3 (da) | 2003-12-22 |
| CN1223582A (zh) | 1999-07-21 |
| JP2001508028A (ja) | 2001-06-19 |
| CO4940509A1 (es) | 2000-07-24 |
| PL331049A1 (en) | 1999-06-21 |
| EP0914122A1 (de) | 1999-05-12 |
| WO1998002160A1 (en) | 1998-01-22 |
| CA2255073A1 (en) | 1998-01-22 |
| CN1145481C (zh) | 2004-04-14 |
| BR9710467A (pt) | 1999-08-17 |
| US5912259A (en) | 1999-06-15 |
| TR199900040T2 (xx) | 1999-04-21 |
| IL127487A (en) | 2002-04-21 |
| HRP970362A2 (en) | 1998-04-30 |
| DE69725147T2 (de) | 2004-07-22 |
| EP0914122B1 (de) | 2003-09-24 |
| AU726664B2 (en) | 2000-11-16 |
| NO990076D0 (no) | 1999-01-08 |
| ES2205247T3 (es) | 2004-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| DE69835823D1 (de) | Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon | |
| BG104686A (en) | Glycine transport inhibitors | |
| ATE207352T1 (de) | Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen | |
| ATE258067T1 (de) | Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält | |
| ATE110958T1 (de) | Verwendung von sertralin zur behandlung verfrühter ejakulation. | |
| DE69218255D1 (de) | Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons | |
| ATE181235T1 (de) | Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| ATE390130T1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
| WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
| ATE294582T1 (de) | Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE69725147D1 (de) | Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin | |
| DE69533311D1 (de) | Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen | |
| ATE216237T1 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| DE69626916D1 (de) | Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten | |
| ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| ATE271881T1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
| ATE263573T1 (de) | Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz | |
| DE69632117D1 (de) | Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| DE69620394D1 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
| DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| EP0790250A3 (de) | Inhibitoren des biogenen Amin Transportes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0914122 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |